VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
CVS
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
CVSCVS Health Corporation
$104.34$133.1B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksCVSCash Flow

CVS Health Corporation (CVS) Cash Flow Statement

30Y historyFree accessUpdated daily

Cash flow remains inconsistent, highlighted by an OCF/NI ratio that swung from -8.56 in 2024Q3 to 1.44 in 2026Q1, complicating capital allocation.

CVS Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Cash from Operations10.33B10.64B9.11B13.43B16.18B18.27B15.87B12.85B8.87B8.01B10.14B8.54B8.14B5.78B6.67B5.86B4.78B4.04B3.95B3.23B1.74B1.61B914.2M968.9M1.2B680.6M780.2M726.3M292.4M-105.8M327.2M
Operating CF Margin %-2.65%2.44%3.75%5.02%6.25%5.9%5%4.56%4.33%5.71%5.57%5.84%4.56%5.42%5.47%4.99%4.11%4.51%4.23%3.98%4.36%2.99%3.64%4.98%3.06%3.88%4.01%1.91%-0.77%2.77%
Operating CF Growth %243.78%16.82%-32.17%-17.01%-11.43%15.13%23.48%44.93%10.72%-21.04%18.76%4.94%40.71%-13.31%13.92%22.54%18.44%2.23%22.21%85.36%8.08%76.34%-5.65%-19.58%77.02%-12.77%7.42%148.39%376.37%-132.34%-28.87%
Net Income2.93B1.73B4.59B8.37B4.33B7.99B7.19B6.63B-596M6.62B5.32B5.24B4.64B4.59B3.86B3.46B3.42B3.7B3.21B2.64B1.37B1.22B959.3M847.3M716.6M413.2M746M635.1M384.5M105.9M208.2M
Depreciation & Amortization1.11B4.61B4.6B4.37B4.22B4.49B4.44B4.37B2.72B2.48B2.48B2.09B1.93B1.87B1.75B1.57B1.47B1.39B1.27B1.09B733.3M589.1M439.9M341.7M310.3M320.8M296.6M277.9M249.7M242.6M262.8M
Stock-Based Compensation276M535M540M588M447M484M400M453M280M234M222M230M165M141M132M135M150M165M92M000000000000
Deferred Taxes620M102M-572M-676M-2.03B-402M-570M-654M87M-1.33B18M-252M-58M-86M-111M144M30M48M-3M40.1M98.2M13.5M-7.2M41.1M71.8M-83.5M43.8M124.8M80.6M-140.4M116.4M
Other Non-Cash Items7.11B5.14B-153M765M2.39B1.85B1.24B548M6.49B421M778M-14M521M0348M-53M00078M69.9M0000352.5M00188.6M466.4M146.6M
Working Capital Changes-2.9B-1.47B109M15M6.82B3.86B3.16B1.5B-112M-416M1.33B1.24B934M-734M687M604M-294M-1.26B-628M-620M-527.9M-215.2M-477.8M-261.2M106.1M-322.4M-306.2M-311.5M-611M-780.3M-406.8M
Change in Receivables-1.65B-3.5B-1.3B-6.26B-2.97B-2.7B-1.51B-2.16B-1.14B-941M-243M-1.59B-737M-2.21B-387M-748M532M-86M-291M279.7M-540.1M-83.1M-48.4M-311.1M-53.1M-141.7M-86.7M-48.9M-197.9M-82.5M-800K
Change in Inventory0------------------------------
Change in Payables326M3.85B2.33B3.62B4.26B2.9B2.77B3.55B2.33B1.71B2.19B2.83B1.74B1.02B1.15B1.13B-40M4M-64M000000000000
Cash from Investing-5.98B-5.87B-7.61B-20.89B-5.05B-5.26B-5.53B-3.34B-43.28B-2.88B-2.47B-13.42B-4.04B-1.83B-1.85B-2.41B-1.64B-1.07B-4.58B-3.08B-4.59B-911.6M-3.16B-753.6M-735.8M-536.8M-640.5M-566.4M-585.4M160.8M23.4M
Capital Expenditures-2.94B-2.83B-2.78B-3.03B-2.73B-2.52B-2.44B-2.46B-2.04B-1.92B-2.22B-2.37B-2.14B-1.98B-2.03B-1.87B-2B-2.55B-2.18B-1.81B-1.77B-1.5B-1.35B-1.12B-1.11B-713.6M-695.3M-722.7M-502.3M-341.6M-702.8M
CapEx % of Revenue0.72%0.7%0.75%0.85%0.85%0.86%0.91%0.96%1.05%1.04%1.25%1.54%1.53%1.57%1.65%1.75%2.09%2.59%2.49%2.37%4.04%4.04%4.41%4.22%4.59%3.21%3.46%3.99%3.29%2.48%5.94%
Acquisitions0------------------------------
Investments-------------------------------
Other Investing-415M26M101M68M85M122M101M47M21M298M267M446M526M654M552M596M541M1.58B19M706.9M1.4B583.8M478.1M501.2M466.5M335.9M318.1M257.4M50.5M192.7M240.4M
Cash from Financing-4.93B-4.94B-1.14B2.68B-10.52B-11.36B-7.7B-7.65B36.82B-6.75B-6.76B4.88B-5.69B-1.24B-4.86B-3.46B-2.8B-3.23B929M377.9M2.87B-579.4M1.8B-72.5M-4.9M-244.8M-32.4M-110.7M281.3M-369.3M-24.7M
Debt Issued (Net)0------------------------------
Equity Issued (Net)353M394M-3.02B-2.01B-3.5B0000-4.36B-4.46B-5B-4B-3.98B-4.33B-3B-1.5B-2.48B-23M-4.82B187.6M178.4M129.8M38.3M34M-81.7M-65.4M20.4M121.1M169.1M128.5M
Dividends Paid-3.4B-3.4B-3.37B-3.13B-2.91B-2.63B-2.62B-2.6B-2.04B-2.05B-1.84B-1.58B-1.29B-1.1B-829M-674M-479M-439M-383M-322.4M-140.9M-131.6M-119.8M-105.2M-104.9M-105.2M-104.8M-104.7M-102.5M-87.6M-137.5M
Share Repurchases00-3.02B-2.01B-3.5B0000-4.36B-4.46B-5B-4B-3.98B-4.33B-3B-1.5B-2.48B-23M-5.37B00000-129M-163.2M0000
Other Financing-180M1.96B202M-105M102M536M601M269M592M257M154M238M527M562M838M424M308M266M381M97.8M42.6M000000000-25.8M
Net Change in Cash-639M-172M359M-4.78B614M1.65B2.63B1.85B2.4B-1.62B912M-22M-1.61B2.71B-38M-14M341M-266M296M525.9M17.3M121.1M-450.9M142.8M464.1M-101M107.3M49.2M-11.7M-314.3M-180.9M
Free Cash Flow7.39B7.81B6.33B10.39B13.45B15.74B13.43B10.39B6.83B6.09B7.92B6.17B6B3.8B4.64B3.98B2.77B1.49B1.77B1.42B-26.5M116.7M-433.5M-152.8M96M-33M84.9M3.6M-209.9M-447.4M-375.6M
FCF Margin %1.81%1.94%1.7%2.91%4.17%5.39%5%4.05%3.51%3.3%4.46%4.03%4.31%3%3.77%3.72%2.9%1.51%2.02%1.87%-0.06%0.32%-1.42%-0.57%0.4%-0.15%0.42%0.02%-1.37%-3.25%-3.17%
FCF Growth %24.46%23.41%-39.14%-22.71%-14.58%17.26%29.23%52.18%12.14%-23.09%28.27%2.85%57.96%-18.14%16.49%43.62%86.55%-15.85%24.05%5475.09%-122.71%126.92%-183.7%-259.17%390.91%-138.87%2258.33%101.72%53.08%-19.12%-445.14%
FCF per Share5.786.145.018.0610.1711.8510.227.966.545.957.345.485.133.103.632.962.011.031.201.04-0.030.14-0.53-0.190.12-0.040.110.00-0.26-0.57-0.88
FCF Conversion (FCF/Net Income)2.52x6.02x1.97x1.61x3.75x2.28x2.21x1.94x-14.92x1.21x1.91x1.63x1.75x1.26x1.73x1.69x1.39x1.09x1.23x1.22x1.27x1.32x0.99x1.14x1.68x1.65x1.05x1.14x0.76x-1.19x1.57x
Interest Paid0000000000000000583M00000000000000
Taxes Paid00000000000000002.22B00000000000000

Key Metrics

Growth RegimeStable
ProfitabilityStrained
Balance SheetStrained
Cash FlowMixed
Top Statement Risk

Medicare Advantage utilization volatility

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Earnings Quality and Cash Divergence

Based on the provided quarterly data, the relationship between net income and operating cash flow remains highly volatile, with the OCF/NI ratio swinging from a negative 8.56 in 2024Q3 to a positive 1.44 in 2026Q1, indicating significant disconnects between accounting profits and actual cash generation.

The extreme variance in the OCF/NI ratio suggests that GAAP net income is frequently distorted by non-cash charges and large working capital swings, particularly within the insurance segment. Investors should monitor whether this volatility reflects genuine operational instability or merely the timing of medical claim settlements.

Free Cash Flow Margin Volatility

As reported in financial statements, CVS's free cash flow trajectory has been inconsistent, with margins fluctuating from a negative 3.8% in 2023Q4 to a peak of 4.7% in 2024Q1, highlighting the difficulty in maintaining stable cash conversion amidst shifting healthcare utilization and integration costs.

The erratic nature of FCF margins suggests that the company's ability to generate surplus cash is highly sensitive to the underlying medical benefit ratio and seasonal claim patterns. This lack of predictability complicates the assessment of the firm's long-term capacity to fund dividends and debt reduction.

Working Capital Swings Obscure Performance

According to recent SEC filings, CVS has experienced massive quarterly fluctuations in working capital, including a $6.0B outflow in 2023Q4 and a $2.7B inflow in 2024Q1, which suggests that the company's cash flow is heavily influenced by the timing of insurance premiums and pharmacy payables.

These large working capital movements appear to mask the underlying cash-generating capability of the core business segments. Analysts should investigate whether these swings are indicative of structural changes in payment cycles or simply the result of managing a complex, multi-segment healthcare delivery network.

Capital Allocation Under Margin Pressure

Based on reported figures, CVS has maintained consistent dividend payments of approximately $840M per quarter, even as free cash flow turned negative in multiple periods, suggesting a commitment to shareholder returns that may be increasingly difficult to sustain given the current thin net margin profile.

The reliance on debt to fund operations and acquisitions, coupled with persistent dividend outflows, warrants further investigation into the sustainability of the current capital allocation strategy. The lack of significant share repurchases in recent quarters may reflect management's need to preserve liquidity in a strained environment.

CVS — Frequently Asked Questions

Quick answers to the most common questions about buying CVS stock.

How much cash does CVS Health Corporation (CVS) generate from operations?

CVS Health Corporation (CVS) generated $10.64B in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is CVS Health Corporation's free cash flow?

CVS Health Corporation (CVS) generated $7.81B in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is CVS Health Corporation's capital expenditure (CapEx)?

CVS Health Corporation (CVS) spent $2.83B on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does CVS Health Corporation distribute cash to shareholders?

In 2025, CVS Health Corporation (CVS) returned $3.40B to shareholders via cash dividends. This shows the company's commitment to returning capital to its equity investors.